Investor Relations

Delivering value to our shareholders with utmost transparency and timely information.

At Mega Lifesciences public company limited

Investor Relations is responsible for delivering value to our shareholders by communicating all the necessary information on a regular basis.

Investment Highlights

Market leading own consumer health and pharmaceutical brands in fast growing developing markets.

FINANCIAL PERFORMANCE IN 3M23

Overall operating revenue
THB mn
(down by 2.4% YoY)
Gross profit
THB mn
representing 43.6% of operating revenue
SG&A expenses
THB mn
representing 27.6% of operating revenue
Reported net profit
THB mn
(down by 26.1% YoY)

Latest Documents

Read our recent and archived releases, Financial statements, Quarterly results, Presentations, Publications and One Reports.

Financial Statement
Quarter 1/2023
Download
MD&A
Quarter 1/2023
Download
Presentation and Webcast
The Opportunity Day Q1/2023
View Webcast Download
Form 56-1 One Report
Form 56-1 One Report 2022
Download
Resource Center

SET Announcements

12 May 2023
Management Discussion and Analysis Quarter 1 Ending 31 Mar 2023
Read More
12 May 2023
Financial Statement Quarter 1/2023 (Reviewed)
Read More
12 May 2023
Financial Performance Quarter 1 (F45) (Reviewed)
Read More

IR Calendar

14
Aug
2023
2Q23 earnings announcement

IR CONTACT

  • Mr. Manoj Gurbuxani (Primary contact)
  • Mr. Francis Rego
  • Ms. Sujintana Boonworapat
  • Ms. Laila Mitnoi (IR Co-ordinator)
  • Mr. Thomas Abraham
  • Mr. Vivek Dhawan
  • investor@megawecare.com
  • +66 2 769 4230